Post-traumatic stress disorder (PTSD) sits at a strange spot in the HBOT debate. Patient demand is high.
Several clinical trials have run. The largest, best-controlled one — the Department of Defense BIMA study — found no benefit over sham.
We trace the trial record from 2014 to 2026 below. The picture is more nuanced than either advocates or skeptics typically present.
The FDA has cleared HBOT for 13 specific uses. PTSD is not among them. Use of HBOT for PTSD is off-label.
The VA system has studied HBOT for PTSD extensively. It has not adopted HBOT as standard care.
The trial record so far
The HBOT-for-PTSD trial record runs through several major studies. We summarize them below.
The Wolf et al. 2012 trial randomized 50 service members with chronic mild traumatic brain injury and PTSD. The trial used a sham comparator (1.3 ATA room air).
Both groups improved equally. The authors interpreted this as a placebo effect.
The Cifu et al. 2014 trial — also called the HOPPS substudy — examined PTSD symptoms in TBI patients.
Both HBOT and sham arms showed improvement. The difference between groups was not statistically significant.
The Harch et al. 2017 study reported benefit at 1.5 ATA in 16 veterans with PTSD. The trial was open-label with no control group.
The improvement was real but cannot be separated from placebo effect.
The BIMA trial (DoD, 2018) is the largest and most rigorously controlled trial to date. It enrolled 71 military service members with chronic mild TBI and PTSD. The HBOT arm (1.5 ATA, 40 sessions) showed no significant difference from the sham arm on PTSD symptoms.
The 2022 Israeli RCT
A different research team published an HBOT trial for PTSD in combat veterans (Doenyas-Barak 2022). The trial enrolled 35 Israeli veterans with combat-related PTSD.
Patients in the HBOT arm received 60 sessions at 2.0 ATA over 12 weeks. The control arm received standard psychotherapy and pharmacotherapy. The trial reported significant improvement on the Clinician-Administered PTSD Scale.
The study has been criticized on several grounds. First, the control was not a sham chamber — just usual care. Patients knew which arm they were in.
Second, the protocol was 60 sessions at 2.0 ATA. The earlier DoD trials used 40 sessions at 1.5 ATA. The pressure and dose are not directly comparable.
Third, the sample size was small (n=35). The effect estimate has wide confidence intervals.
The Israeli result is interesting but does not overturn the larger, better-controlled BIMA trial. It does suggest that higher-pressure, longer-protocol HBOT might warrant further study.
What the VA actually does
The VA has studied HBOT for PTSD in several research protocols. It has not adopted HBOT as standard care.
The VA's current PTSD clinical practice guidelines recommend trauma-focused psychotherapy (such as prolonged exposure or cognitive processing therapy) and SSRIs as first-line treatment.
HBOT is not mentioned as a recommended treatment. The VA continues to run HBOT research, particularly through the Office of Research and Development, but the data has not crossed the bar for standard adoption.
A handful of VA medical centers offer HBOT through research protocols. Patients interested in joining a trial should consult ClinicalTrials.gov for current PTSD HBOT studies.
The mechanism question
The biological case for HBOT in PTSD has two parts.
First, PTSD often coexists with mild TBI in military populations. If HBOT helps mild TBI tissue recovery, it might indirectly help PTSD symptoms. The TBI evidence is similarly weak — the HOPPS trial (2015) and BIMA trial (2018) both found no benefit.
Second, HBOT may modulate inflammation and neuroplasticity through hyperoxia-induced changes in gene expression. Animal studies show short-term changes in brain-derived neurotrophic factor (BDNF) and other markers.
These are real mechanisms in lab settings. Whether they translate to durable PTSD symptom relief in humans is the open question.
The best-controlled trials say no. Smaller, less-controlled trials say maybe.
What clinics are charging
Off-label HBOT for PTSD typically runs 40-60 sessions at 1.5-2.0 ATA. Per-session pricing usually runs $250 to $500 at hard-shell hospital-grade chambers from Sechrist Industries or Perry Baromedical.
A full course thus costs $10,000 to $30,000 out of pocket. Insurance does not cover HBOT for PTSD.
Some wellness clinics market soft-shell 1.3 ATA HBOT at OxyHealth or Summit to Sea chambers for PTSD at $50-100 per session. The mechanistic case for 1.3 ATA is weaker than for 2.0 ATA, given the much smaller arterial oxygen rise. Restore Hyper Wellness sites offer this tier in many states.
Some Florida and California longevity programs offer a 60-session protocol at near $50,000 for general "chronic condition" recovery. PTSD veterans enroll. There is no published program-specific trial for PTSD outcomes at these chains.
Our comparison of mild vs medical HBOT lays out the dose difference in detail.
How to evaluate an HBOT clinic for PTSD
Several questions cut through the marketing.
What protocol does the clinic use? Most published PTSD trials used 40 sessions at 1.5 ATA (BIMA) or 60 sessions at 2.0 ATA (Israeli 2022). Anything outside that range needs justification.
What is the chamber make and model? Look up the K-number on openFDA.
Hospital-grade hard-shell chambers from Sechrist Industries or Perry Baromedical are the standard. Soft-shell OxyHealth or Summit to Sea chambers at 1.3 ATA are a different drug.
Is the clinic UHMS-accredited? Check the UHMS directory. Most UHMS-accredited sites do not accept off-label PTSD cases because their FDA-approved wound work fills capacity.
What other PTSD treatments have you tried? Evidence-based trauma-focused therapy (PE, CPT, EMDR) and SSRIs have stronger evidence than HBOT. Most patients should try these first.
What does the clinic say about the BIMA trial result? A clinic that has no answer for the negative BIMA result is selling rather than informing.
Aviv Clinics: the elephant outside the room
Aviv Clinics in Florida is the most visible US destination for off-label HBOT, including PTSD cases. Its protocol is 60 sessions at 2.0 ATA for $50,000.
The supporting research is from the Sagol Center in Israel (Hadanny et al. 2020) and focuses on cognitive aging, not PTSD. The Aviv marketing implies broad chronic-condition benefit. The trial evidence is for a different patient population.
We unpack the Aviv evidence-marketing gap in our Aviv evidence-vs-marketing analysis. The TL;DR: the trials are real but smaller and less generalizable than the marketing implies.
The institutional silence pattern
Major US academic centers do not promote HBOT for PTSD. Mayo Clinic, Cleveland Clinic, Johns Hopkins, and the major VA research centers all have HBOT capability and PTSD expertise.
None offer HBOT as standard PTSD care. None advertise it. None publish supportive trials in major journals.
That silence is informative. We unpack the pattern in our institutional silence on HBOT analysis.
Research-active centers see the same data the wellness market sees. They have chosen not to translate that into clinical practice.
What better research would look like
The BIMA trial is the current evidence ceiling. A trial that would change practice would need several things.
A larger sample size. BIMA had n=71. A definitive trial would need 200+.
A higher-pressure protocol. BIMA used 1.5 ATA. The 2022 Israeli trial used 2.0 ATA and showed gains.
A direct comparison at 2.0 ATA in a US military population would resolve the dose question.
A true sham control. The Israeli trial used usual care, not a sham chamber. A sham-controlled higher-dose trial is the missing piece.
Several such trials are listed on ClinicalTrials.gov as of 2026. Results are pending.
Bottom line
The strongest controlled trial (BIMA, 2018) found HBOT no better than sham for PTSD. Smaller, less-controlled trials show gains that may or may not survive better methodology.
If you are a veteran with PTSD, start with the VA's evidence-based pathway: trauma-focused psychotherapy plus medication management. These have the strongest evidence and full insurance coverage.
If you have exhausted standard care and are considering HBOT, choose a higher-pressure (2.0+ ATA) hard-shell program in an FDA-cleared chamber. Understand that the trial evidence is weak and insurance will not cover it. See complete FDA-cleared chambers list for the complete chamber-by-chamber list.
Related Reading
- HBOT for ADHD: what the evidence actually shows
- HBOT for long COVID: Shamir RCT detailed analysis
- Institutional silence on HBOT
- Aviv Clinics: evidence vs marketing
- What research shows about HBOT for traumatic brain injury
Frequently asked questions
Is HBOT FDA-approved for PTSD?
No. The FDA has cleared HBOT for 13 specific uses; PTSD is not among them. Use of HBOT for PTSD is off-label.
Does the VA pay for HBOT for PTSD?
No. The VA has not adopted HBOT as standard care for PTSD. Some VA medical centers offer HBOT through research protocols. Patients interested in joining a trial should consult ClinicalTrials.gov.
How strong is the evidence?
Mixed. The largest controlled trial (BIMA, 2018) found HBOT no better than sham. A smaller 2022 Israeli trial showed gains but had methodology limits. Open-label and uncontrolled studies show improvement but cannot rule out placebo effect.
How much does HBOT for PTSD cost?
Hard-shell sessions run $250-$500 each. A 40-60 session course typically costs $10,000-$30,000 out of pocket. Insurance does not cover it.
What treatments have the strongest evidence for PTSD?
Trauma-focused psychotherapy (prolonged exposure, cognitive processing therapy) and SSRIs are first-line per the VA clinical practice guidelines. These have the strongest evidence and full insurance coverage.
Medical disclaimer: This article is informational and does not constitute medical advice. HBOT carries real risks including ear barotrauma, oxygen toxicity, and chamber fire. PTSD is a serious mental health condition that requires care from a qualified mental health professional. If you are in crisis, contact the Veterans Crisis Line (988, press 1) or the 988 Suicide and Crisis Lifeline. The FDA has cleared HBOT for 13 specific uses; PTSD is not among them.
-- The HBOT Finder Team